INVESTING5 Stock Gainers for Friday: VBI Vaccines, Moderna, NovavaxBy Rob LenihanJul 17, 2020 4:23 PM EDT
PRESS RELEASESDynavax To Report Second Quarter 2020 Financial Results And Host Conference Call On August 6, 2020By GlobeNewswireJul 30, 2020 4:05 PM EDT
PRESS RELEASESDynavax And Medigen Announce Collaboration To Develop A Novel Adjuvanted COVID-19 Vaccine CandidateBy GlobeNewswireJul 23, 2020 8:00 AM EDT
PRESS RELEASESDynavax Announces The Appointment Of Two New Board MembersBy GlobeNewswireJul 21, 2020 4:10 PM EDT
INVESTING5 Stock Gainers for Friday: VBI Vaccines, Moderna, NovavaxBy Rob LenihanJul 17, 2020 4:23 PM EDT
PRESS RELEASESDynavax And Mount Sinai Announce Collaboration To Develop A Universal Influenza Vaccine Candidate With CpG 1018 AdjuvantBy GlobeNewswireJul 16, 2020 8:40 AM EDT
PRESS RELEASESDynavax Announces First Participants Dosed In Phase 1 Clinical Trial Evaluating Medicago's COVID-19 Vaccine Candidate With Dynavax's CpG 1018 AdjuvantBy GlobeNewswireJul 14, 2020 8:00 AM EDT
PRESS RELEASESDynavax And Times Pharmacy Announce Partnership To Offer HEPLISAV-B® Hepatitis B Vaccine To Customers Throughout Oahu, With A Focus On People With DiabetesBy GlobeNewswireJul 10, 2020 4:01 PM EDT
PRESS RELEASESDynavax Announces First Participants Dosed In Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals' COVID-19 S-Trimer Vaccine Candidate With CpG 1018 AdjuvantBy GlobeNewswireJun 19, 2020 6:00 AM EDT
PRESS RELEASESDynavax Completes Enrollment Of Clinical Trial Evaluating HEPLISAV-B In Patients Undergoing HemodialysisBy GlobeNewswireJun 9, 2020 8:00 AM EDT
PRESS RELEASESDynavax To Present At The William Blair 40th Annual Growth Stock ConferenceBy GlobeNewswireMay 28, 2020 4:05 PM EDT
PRESS RELEASESDynavax Technologies Announces Closing Of $80.5 Million Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional SharesBy GlobeNewswireMay 27, 2020 4:05 PM EDT
PRESS RELEASESDynavax Technologies Announces Pricing Of $70.0 Million Public Offering Of Common StockBy GlobeNewswireMay 21, 2020 9:00 PM EDT
PRESS RELEASESDynavax Technologies Announces Proposed Public Offering Of Common StockBy GlobeNewswireMay 21, 2020 4:01 PM EDT
INVESTINGGilead in Talks With Chemical and Pharma Makers on Global Remdesivir ProductionBy Tom BemisMay 5, 2020 6:31 PM EDT
PRESS RELEASESDynavax Reports Interim Analysis Of Ongoing Clinical Trial Evaluating HEPLISAV-B In Patients Undergoing HemodialysisBy GlobeNewswireApr 28, 2020 4:10 PM EDT
PRESS RELEASESDynavax To Report First Quarter 2020 Financial Results And Host Conference Call On May 7, 2020By GlobeNewswireApr 23, 2020 4:10 PM EDT
INVESTINGGilead Sees Promising Results in Study of Remdesivir Treatment for COVID-19 Patients: ReportBy Tom BemisApr 16, 2020 7:09 PM EDT
PRESS RELEASESDynavax And Sinovac Announce Collaboration To Develop A Coronavirus (COVID-19) VaccineBy GlobeNewswireApr 16, 2020 7:30 AM EDT
INVESTINGArcus Shares Soar on Report Gilead is Considering Acquiring StakeBy Tom BemisApr 15, 2020 6:36 PM EDT
PRESS RELEASESDynavax Donates 10,000 Doses Of HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Vaccine To Emergency Healthcare Providers And Hospital Staff To Protect Against Hepatitis B Infections Amidst COVID-19 PandemicBy GlobeNewswireApr 8, 2020 8:00 AM EDT
PRESS RELEASESDynavax Provides Business Update On COVID-19 Pandemic ImpactBy GlobeNewswireApr 2, 2020 4:30 PM EDT
PRESS RELEASESDynavax And Clover Biopharmaceuticals Announce Research Collaboration To Evaluate Coronavirus (COVID-19) Vaccine Candidate With CpG 1018 AdjuvantBy GlobeNewswireMar 24, 2020 8:30 AM EDT
PRESS RELEASESDynavax Announces Collaboration With The University Of Queensland And The Coalition For Epidemic Preparedness (CEPI) Focused On The Development Of A Coronavirus (COVID-19) VaccineBy GlobeNewswireMar 2, 2020 8:00 AM EST
PRESS RELEASESDynavax To Present At The Cowen 40th Annual Health Care ConferenceBy GlobeNewswireFeb 18, 2020 4:05 PM EST
